MGNX

In the past six months, MacroGenics reported its first-quarter 2026 financial results in May and second-quarter 2026 financial results in August. A significant event was the completion of the sale of its GMP manufacturing operations to Bora Pharmaceuticals in July 2026 for $122.5 million, aimed at streamlining its operating model and strengthening its financial position. The company also announced a $10 million milestone payment from Gilead in August 2026, following Gilead's exercise of an option to license a preclinical bispecific program, and was set to receive a milestone payment from Sanofi for the recent approval of TZIELD® in June 2026. Clinical updates on its ongoing Phase 1 study for MGC026 were provided in July 2026. The stock has shown a significant increase of 132.00% over the past year (as of September 28, 2026), but experienced a 12.82% fall in the month prior to June 22, 2022.